CRP and inflammatory bowel disease: Dierckx et al. showed a consistent decrease in GlycA levels in IBD patients during therapy with adalimumab, infliximab, vedolizumab, and ustekinumab compared to other biomarkers such as fecal calprotectin or CRP [124], which have had a moderate response at most in some patients with IBD [198].